ArticleImmunology2004
Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts.
Article in Immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.Cellular immunology · 2019Article
- Mrp1 is involved in lipid presentation and iNKT cell activation by Streptococcus pneumoniae.Nature communications · 2018Article
- The Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens.Frontiers in immunology · 2018Review
- Ceramide and Exosomes: A Novel Target in Cancer Biology and Therapy.Advances in cancer research · 2018Review
- Immunometabolic Activation of Invariant Natural Killer T Cells.Frontiers in immunology · 2018Review
- ATP Binding Cassette Transporter ABCA7 Regulates NKT Cell Development and Function by Controlling CD1d Expression and Lipid Raft Content.Scientific reports · 2017Article
- Bcl-xL regulates CD1d-mediated antigen presentation to NKT cells by altering CD1d trafficking through the endocytic pathway.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Article
- Type II NKT cells facilitate Alum-sensing and humoral immunity.Journal of leukocyte biology · 2012Article
- Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- The split personality of NKT cells in malignancy, autoimmune and allergic disorders.Immunotherapy · 2011Review
- Targeting the diverse immunological functions expressed by hepatic NKT cells.Expert opinion on therapeutic targets · 2011Review
- Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes.Clinical and experimental immunology · 2011Article
- Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunity.The Journal of clinical investigation · 2011Article
- Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.PloS one · 2011Article
- Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.Seminars in immunology · 2010Review
- CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies.Infection and immunity · 2010Article
- Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- How do natural killer T cells help B cells?Expert review of vaccines · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
CD1 molecules are non-polymorphic major histocompatibility complex class I-related proteins that bind and present glycolipid antigens to T-cell antigen receptors (TCR) expressed by alphabeta T cells or natural killer-like T cells (NKT). Anti-metastatic properties of NKT cells reactive to the CD1d-binding antigen alpha-galactosylceramide (alpha-GalCer) are now being explored as a contributor to tumour cell killing. In this study, we tested the hypothesis that presentation of alpha-GalCer by murine CD1d (mCD1d) to mCD1d-restricted NKT cells was facilitated by plasma membrane glycolipid rafts. Confocal microscopy of mCD1d-transfected A20 B cells (A20mCD1d) demonstrated that mCD1d was raft-localized. This observation was confirmed by immunoblotting of raft fractions isolated on sucrose density gradients. Raft disruption by the cholesterol-binding agent nystatin, or short-chain ceramides, inhibited presentation of low concentrations of alpha-GalCer to NKT cells. Inhibition of antigen presentation was reversed by treatment of A20mCD1d cells with higher alpha-GalCer concentrations, or removal of raft-disrupting agents. These data indicate that partitioning of mCD1d into membrane rafts increases the capacity of antigen-presenting cells to present limiting quantities of glycolipid antigens, perhaps by stabilizing mCD1d/antigen structures on the plasma membrane and optimizing TCR engagement on NKT cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.